Selective serotonin reuptake inhibitor (SSRI) medications are the most common antidepressant treatment used during pregnancy and the postpartum period. Up to 10% of pregnant women are prescribed SSRIs. Serotonin plays an integral part in neurodevelopment, and questions have been raised about the placental transfer of SSRIs and the effects of preventing reuptake of presynaptic serotonin on fetal neurodevelopment. Preclinical data is beginning to document a role of early exposure to SSRIs in long-term developmental outcomes related to a number of brain regions, such as the hippocampus, cortex and cerebellum. To date, the majority of preclinical work has investigated the developmental effects of SSRIs in the offspring of healthy mothers; however, more research is needed on the effects of these medications in the face of maternal adversity. This minireview will highlight emerging evidence from clinical and preclinical studies investigating the impact of perinatal SSRI exposure on brain development and neural plasticity.

1.
Pawluski JL, Galea LA: The role of reproductive experience on hippocampal function and plasticity; in Bridges R (ed): Neurobiology of the Parental Brain. Boston, Academic Press, 2008, pp 493–508.
2.
Morrison JL, Riggs KW, Rurak DW: Fluoxetine during pregnancy: impact on fetal development. Reprod Fertil Dev 2005;17:641–650.
3.
Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR: Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004;103:698–709.
4.
Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C: Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63:898–906.
5.
Huizink AC, de Medina PG, Mulder EJ, Visser GH, Buitelaar JK: Psychological measures of prenatal stress as predictors of infant temperament. J Am Acad Child Adolesc Psychiatry 2002;41:1078–1085.
6.
Glover V, O’Connor TG, O’Donnell K: Prenatal stress and the programming of the hpa axis. Neurosci Biobehav Rev 2010;35:17–22.
7.
Davis EP, Glynn LM, Schetter CD, Hobel C, Chicz-Demet A, Sandman CA: Prenatal exposure to maternal depression and cortisol influences infant temperament. J Am Acad Child Adolesc Psychiatry 2007;46:737–746.
8.
Fleschler R, Peskin MF: Selective serotonin reuptake inhibitors (SSRIs) in pregnancy: a review. MCN Am J Matern Child Nurs 2008;33:355–361; quiz 362–353.
9.
Cooper WO, Willy ME, Pont SJ, Ray WA: Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007;196:544.e1–e5.
10.
Homberg JR, Schubert D, Gaspar P: New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 2010;31:60–65.
11.
Oberlander TF, Gingrich JA, Ansorge MS: Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharmacol Ther 2009;86:672–677.
12.
Lucki I: The spectrum of behaviors influenced by serotonin. Biol Psychiatry 1998;44:151–162.
13.
Di Pino G, Moessner R, Lesch KP, Lauder JM, Persico AM: Roles for serotonin in neurodevelopment: more than just neural transmission. Curr Neuropharmacol 2004;2:403–417.
14.
Robbins TW, Granon S, Muir JL, Durantou F, Harrison A, Everitt BJ: Neural systems underlying arousal and attention: implications for drug abuse. Ann N Y Acad Sci 1998;846:222–237.
15.
Whitaker-Azmitia PM, Druse M, Walker P, Lauder JM: Serotonin as a developmental signal. Behav Brain Res 1996;73:19–29.
16.
Whitaker-Azmitia PM, Peroutka SJ: The Neuropharmacology of Serotonin. New York, New York Academy of Sciences, 1990.
17.
Huizink AC, Mulder EJ, Buitelaar JK: Prenatal stress and risk for psychopathology: specific effects or induction of general susceptibility? Psychol Bull 2004;130:115–142.
18.
Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL: Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372–2383.
19.
Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, Lipworth L, Sorensen HT: Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17:701–704.
20.
Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579–587.
21.
Laine K, Heikkinen T, Ekblad U, Kero P: Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003;60:720–726.
22.
Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W: Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure. Pediatrics 2005;115:411–425.
23.
Whitaker-Azmitia PM: Serotonin and brain development: role in human developmental diseases. Brain Res Bull 2001;56:479–485.
24.
Pawluski JL, Galea LA, Brain U, Papsdorf M, Oberlander TF: Neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors. Pediatrics 2009;124:e662–e670.
25.
Devlin AM, Brain U, Austin J, Oberlander TF: Prenatal exposure to maternal depressed mood and the MTHFR C677T variant affect SLC6A4 methylation in infants at birth. PLoS ONE 2010;5:e12201.
26.
Pham N, Fazio V, Cucullo L, Teng Q, Biberthaler P, Bazarian JJ, Janigro D: Extracranial sources of S100B do not affect serum levels. PLoS One 2010;5:e12691
27.
Whitaker-Azmitia PM, Murphy R, Azmitia EC: Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res 1990;528:155–158.
28.
Haring JH, Hagan A, Olson J, Rodgers B: Hippocampal serotonin levels influence the expression of S100 beta detected by immunocytochemistry. Brain Res 1993;631:119–123.
29.
Manev H, Manev R: Nomen est omen: do antidepressants increase p11 or S100A10? J Biomed Discov Collab 2006;1:5.
30.
Bhattacharyya A, Oppenheim RW, Prevette D, Moore BW, Brackenbury R, Ratner N: S100 is present in developing chicken neurons and Schwann cells and promotes motor neuron survival in vivo. J Neurobiol 1992;23:451–466.
31.
Gonzalez-Martinez T, Perez-Pinera P, Diaz-Esnal B, Vega JA: S-100 proteins in the human peripheral nervous system. Microsc Res Tech 2003;60:633–638.
32.
Selinfreund RH, Barger SW, Pledger WJ, Van Eldik LJ: Neurotrophic protein s100 beta stimulates glial cell proliferation. Proc Natl Acad Sci USA 1991;88:3554–3558.
33.
Branchi I, Francia N, Alleva E: Epigenetic control of neurobehavioural plasticity: the role of neurotrophins. Behav Pharmacol 2004;15:353–362.
34.
Mercier G, Lennon AM, Renouf B, Dessouroux A, Ramauge M, Courtin F, Pierre M: Map kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J Mol Neurosci 2004;24:207–216.
35.
Karpova NN, Lindholm J, Pruunsild P, Timmusk T, Castren E: Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. Eur Neuropsychopharmacol 2009;19:97–108.
36.
Byrd RA, Markham JK: Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits. Fundam Appl Toxicol 1994;22:511–518.
37.
Pohland RC, Byrd TK, Hamilton M, Koons JR: Placental transfer and fetal distribution of fluoxetine in the rat. Toxicol Appl Pharmacol 1989;98:198–205.
38.
Borue X, Chen J, Condron BG: Developmental effects of SSRIs: lessons learned from animal studies. Int J Dev Neurosci 2007;25:341–347.
39.
Del Rio J, Montero D, De Ceballos ML: Long-lasting changes after perinatal exposure to antidepressants. Prog Brain Res 1988;73:173–187.
40.
Weaver KJ, Paul IA, Lin RC, Simpson KL: Neonatal exposure to citalopram selectively alters the expression of the serotonin transporter in the hippocampus: dose-dependent effects. Anat Rec (Hoboken) 2010;293:1920–1932.
41.
Andrews MH, Matthews SG: Programming of the hypothalamo-pituitary-adrenal axis: serotonergic involvement. Stress 2004;7:15–27.
42.
Romijn HJ, Hofman MA, Gramsbergen A: At what age is the developing cerebral cortex of the rat comparable to that of the full-term newborn human baby? Early Hum Dev 1991;26:61–67.
43.
Swerts CA, Costa AM, Esteves A, Borato CE, Swerts MS: Effects of fluoxetine and imipramine in rat fetuses treated during a critical gestational period: a macro and microscopic study. Rev Bras Psiquiatr 2010;32:152–158.
44.
Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, Buelke-Sam J: A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 1994;23:194–205.
45.
Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RC, Paul IA: Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2006;31:47–57.
46.
Zusso M, Debetto P, Guidolin D, Barbierato M, Manev H, Giusti P: Fluoxetine-induced proliferation and differentiation of neural progenitor cells isolated from rat postnatal cerebellum. Biochem Pharmacol 2008;76:391–403.
47.
Bairy KL, Madhyastha S, Ashok KP, Bairy I, Malini S: Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 2007;79:1–11.
48.
Lisboa SF, Oliveira PE, Costa LC, Venancio EJ, Moreira EG: Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology 2007;80:49–56.
49.
Lee LJ: Neonatal fluoxetine exposure affects the neuronal structure in the somatosensory cortex and somatosensory-related behaviors in adolescent rats. Neurotox Res 2009;15:212–223.
50.
Gentile S: SSRIs in pregnancy and lactation: emphasis on neurodevelopmental outcome. CNS Drugs 2005;19:623–633.
51.
Xu Y, Sari Y, Zhou FC: Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development. Brain Res Dev Brain Res 2004;150:151–161.
52.
Weinstock M: The long-term behavioural consequences of prenatal stress. Neurosci Biobehav Rev 2008;32:1073–1086.
53.
O’Mahony SM, Myint AM, van den Hove D, Desbonnet L, Steinbusch H, Leonard BE: Gestational stress leads to depressive-like behavioural and immunological changes in the rat. Neuroimmunomodulation 2006;13:82–88.
54.
Ishiwata H, Shiga T, Okado N: Selective serotonin reuptake inhibitor treatment of early postnatal mice reverses their prenatal stress-induced brain dysfunction. Neuroscience 2005;133:893–901.
55.
Rayen I, Van den Hove D, Prickaerts J, Steinbusch H, Pawluski JL: Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence. Accepted. PLoS ONE.
56.
Kendall-Tackett K, Hale TW: The use of antidepressants in pregnant and breastfeeding women: a review of recent studies. J Hum Lact 2010;26:187–195.
57.
Lee HJ, Kim JW, Yim SV, Kim MJ, Kim SA, Kim YJ, Kim CJ, Chung JH: Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats. Mol Psychiatry 2001;6:610, 725–728.
58.
Maciag D, Williams L, Coppinger D, Paul IA: Neonatal citalopram exposure produces lasting changes in behavior which are reversed by adult imipramine treatment. Eur J Pharmacol 2006;532:265–269.
59.
Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C: The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009;31:403–413.
60.
Swerts CA, Costa AM, Esteves A, Borato CE, Swerts MS: Effects of fluoxetine and imipramine in rat fetuses treated during a critical gestational period: a macro and microscopic study. Rev Bras Psiquiatr 2010;32:152–158.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.